Indian generics giant Lupin Limited faced “another difficult quarter… despite some good developments” in Q3, said non-executive vice chairman Kamal Sharma on a company earnings call. Residual metformin returns from retail and provision for aged stock returns of oseltamivir saw gross profit margins fall, but a series of promising impending launches could boost the company’s fortunes.
Lupin managing director Nilesh Gupta said: “We are on the path of sustained growth across markets
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?